SU1349698A3 - Способ получени производных пиримидин-2-онов или их солей - Google Patents
Способ получени производных пиримидин-2-онов или их солей Download PDFInfo
- Publication number
- SU1349698A3 SU1349698A3 SU843718401A SU3718401A SU1349698A3 SU 1349698 A3 SU1349698 A3 SU 1349698A3 SU 843718401 A SU843718401 A SU 843718401A SU 3718401 A SU3718401 A SU 3718401A SU 1349698 A3 SU1349698 A3 SU 1349698A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- hydrogen
- alkyl
- lower alkyl
- optionally substituted
- female
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 9
- 150000003839 salts Chemical class 0.000 title claims abstract description 6
- -1 hydroxy, amino Chemical group 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 19
- 239000001257 hydrogen Substances 0.000 claims abstract 19
- 125000000217 alkyl group Chemical group 0.000 claims abstract 18
- 150000002431 hydrogen Chemical class 0.000 claims abstract 15
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 6
- 229910052736 halogen Chemical group 0.000 claims abstract 3
- 150000002367 halogens Chemical group 0.000 claims abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 5
- 241000699670 Mus sp. Species 0.000 claims description 2
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 210000001367 artery Anatomy 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 101150085479 CHS2 gene Proteins 0.000 claims 1
- 241000721701 Lynx Species 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 230000003177 cardiotonic effect Effects 0.000 abstract description 5
- 239000004593 Epoxy Substances 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 229940030600 antihypertensive agent Drugs 0.000 abstract 1
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 229940127218 antiplatelet drug Drugs 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000001382 anti-thrombocytic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 229960004486 desoxycorticosterone acetate Drugs 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- OYGHXRNCHYRYRR-UHFFFAOYSA-N 6-(3,4-dimethoxyphenyl)-1-ethyl-3-methyl-4-(2,4,6-trimethylphenyl)iminopyrimidin-2-one Chemical compound CN1C(=O)N(CC)C(C=2C=C(OC)C(OC)=CC=2)=CC1=NC1=C(C)C=C(C)C=C1C OYGHXRNCHYRYRR-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BMTAFVWTTFSTOG-UHFFFAOYSA-N Butylate Chemical compound CCSC(=O)N(CC(C)C)CC(C)C BMTAFVWTTFSTOG-UHFFFAOYSA-N 0.000 description 1
- IJJUENQVHOKTHU-UHFFFAOYSA-N C1=C(OC)C(OC)=CC=C1C(NC(=O)N1C)=CC1=NC1=C(C)C=C(C)C=C1C Chemical compound C1=C(OC)C(OC)=CC=C1C(NC(=O)N1C)=CC1=NC1=C(C)C=C(C)C=C1C IJJUENQVHOKTHU-UHFFFAOYSA-N 0.000 description 1
- FWDBZJBJTDRIIY-UHFFFAOYSA-N CC(C)(C)[K] Chemical compound CC(C)(C)[K] FWDBZJBJTDRIIY-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB838308290A GB8308290D0 (en) | 1983-03-25 | 1983-03-25 | Pyrimidinone derivatives |
| GB838315542A GB8315542D0 (en) | 1983-06-07 | 1983-06-07 | Pyrimidinone derivatives |
| GB838327859A GB8327859D0 (en) | 1983-10-18 | 1983-10-18 | Pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1349698A3 true SU1349698A3 (ru) | 1987-10-30 |
Family
ID=27262023
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU843718401A SU1349698A3 (ru) | 1983-03-25 | 1984-03-23 | Способ получени производных пиримидин-2-онов или их солей |
| SU853892541A SU1436872A3 (ru) | 1983-03-25 | 1985-03-28 | Способ получени производных пиримидина |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU853892541A SU1436872A3 (ru) | 1983-03-25 | 1985-03-28 | Способ получени производных пиримидина |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US4612376A (OSRAM) |
| EP (1) | EP0123402B1 (OSRAM) |
| KR (1) | KR840008333A (OSRAM) |
| CA (1) | CA1256107A (OSRAM) |
| DE (1) | DE3473875D1 (OSRAM) |
| DK (1) | DK160492C (OSRAM) |
| ES (2) | ES8505972A1 (OSRAM) |
| FI (1) | FI841128A7 (OSRAM) |
| GR (1) | GR81758B (OSRAM) |
| HU (1) | HU195195B (OSRAM) |
| NO (1) | NO841168L (OSRAM) |
| PH (1) | PH22022A (OSRAM) |
| SU (2) | SU1349698A3 (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2170734C2 (ru) * | 1995-09-06 | 2001-07-20 | Кова Ко., Лтд. | Производные пиримидина, фармацевтическая композиция и способ профилактики и лечения болезни |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4612376A (en) * | 1983-03-25 | 1986-09-16 | Fujisawa Pharmaceutical Co., Ltd. | Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent |
| US4598149A (en) * | 1984-03-02 | 1986-07-01 | Merck & Co., Inc. | 3-amino-2-hydroxypropyl of pyrimidin-4-one useful as antihypertensive, cardioprotective, antiarrythmic, and antianginal agents |
| US4649142A (en) * | 1984-06-25 | 1987-03-10 | Fujisawa Pharmaceutical Co., Ltd. | 3,4-dihydro-1,3-disubstituted-6-(substituted phenylimino)-2(1H)-pyrimidinone useful as cardiotonic agent and anti-allergic agent |
| US4708958A (en) * | 1986-09-24 | 1987-11-24 | G. D. Searle & Co. | 6-(imidazolyphenyl)-4-iminopyrimidinones useful as hypotensive agents |
| US5521315A (en) * | 1993-01-12 | 1996-05-28 | Cell Therapeutics, Inc. | Olefin substituted long chain compounds |
| IT1270122B (it) * | 1994-10-04 | 1997-04-28 | Ist Superiore Sanita | 6-benzil-4-ossopirimidine sostituite, processo per la loro preparazione e composizioni farmaceutiche che le contengono |
| US6244121B1 (en) * | 1998-03-06 | 2001-06-12 | Applied Materials, Inc. | Sensor device for non-intrusive diagnosis of a semiconductor processing system |
| EP1599468B1 (en) | 2003-01-14 | 2007-10-03 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| AR045697A1 (es) | 2003-07-14 | 2005-11-09 | Arena Pharm Inc | Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo |
| DOP2006000009A (es) | 2005-01-13 | 2006-08-15 | Arena Pharm Inc | Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina |
| JP5113752B2 (ja) | 2005-08-22 | 2013-01-09 | メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド | Ｌｙｎキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤 |
| CA2678813A1 (en) * | 2007-02-20 | 2008-08-28 | Melior Pharmaceuticals I, Inc. | Methods of identifying activators of lyn kinase |
| AU2008279242A1 (en) * | 2007-07-23 | 2009-01-29 | Melior Discovery, Inc. | Methods of activating IRS-1 and AKT |
| US8552184B2 (en) * | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
| EP2462123B1 (en) * | 2009-08-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
| SG10201500639TA (en) | 2010-01-27 | 2015-03-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| WO2011150300A1 (en) | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
| AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
| US10183949B2 (en) | 2014-08-29 | 2019-01-22 | The University Of Tokyo | Pyrimidinone derivative having autotaxin-inhibitory activity |
| JP6632532B2 (ja) * | 2014-08-29 | 2020-01-22 | 国立大学法人 東京大学 | オートタキシン阻害活性を有するピリミジノン誘導体 |
| CN116850181A (zh) | 2015-01-06 | 2023-10-10 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
| AU2016284162A1 (en) | 2015-06-22 | 2018-02-01 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders |
| AU2018220521A1 (en) | 2017-02-16 | 2019-09-05 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| JP7182605B2 (ja) | 2017-04-10 | 2022-12-02 | メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド | ｌｙｎキナーゼ活性化因子及びＴＲＰＭ８アゴニストを含む組成物及び医薬の製造におけるそれらの使用 |
| WO2019236757A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| CN109053589A (zh) * | 2018-09-30 | 2018-12-21 | 浙江师范大学 | 4-亚胺基四氢嘧啶-2-酮类化合物的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1296371A (OSRAM) * | 1969-02-26 | 1972-11-15 | ||
| AU1108070A (en) * | 1969-03-06 | 1971-08-12 | Imperial Chemical Industries Limited | Pyrimidine derivatives |
| GB1336138A (en) * | 1969-12-10 | 1973-11-07 | Ici Ltd | Process for the production of pyrimidine derivatives |
| US3923807A (en) * | 1973-09-10 | 1975-12-02 | Takeda Chemical Industries Ltd | 6-Aminouracil derivatives |
| US4208366A (en) * | 1978-10-31 | 1980-06-17 | E. I. Du Pont De Nemours And Company | Process for preparing a nonwoven web |
| DE2847693A1 (de) * | 1978-11-03 | 1980-05-22 | Hoechst Ag | Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen |
| US4612376A (en) * | 1983-03-25 | 1986-09-16 | Fujisawa Pharmaceutical Co., Ltd. | Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent |
-
1984
- 1984-03-12 US US06/588,902 patent/US4612376A/en not_active Expired - Fee Related
- 1984-03-14 PH PH30400A patent/PH22022A/en unknown
- 1984-03-14 EP EP84301741A patent/EP0123402B1/en not_active Expired
- 1984-03-14 DE DE8484301741T patent/DE3473875D1/de not_active Expired
- 1984-03-14 GR GR74104A patent/GR81758B/el unknown
- 1984-03-20 KR KR1019840001414A patent/KR840008333A/ko not_active Ceased
- 1984-03-21 FI FI841128A patent/FI841128A7/fi not_active Application Discontinuation
- 1984-03-21 CA CA000450076A patent/CA1256107A/en not_active Expired
- 1984-03-23 DK DK166884A patent/DK160492C/da active IP Right Grant
- 1984-03-23 ES ES530916A patent/ES8505972A1/es not_active Expired
- 1984-03-23 SU SU843718401A patent/SU1349698A3/ru active
- 1984-03-23 HU HU841170A patent/HU195195B/hu not_active IP Right Cessation
- 1984-03-23 NO NO841168A patent/NO841168L/no unknown
- 1984-11-30 ES ES538190A patent/ES8601922A1/es not_active Expired
-
1985
- 1985-03-28 SU SU853892541A patent/SU1436872A3/ru active
-
1986
- 1986-06-05 US US06/870,826 patent/US4746664A/en not_active Expired - Fee Related
-
1988
- 1988-03-25 US US07/173,584 patent/US4824851A/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| ВейганД-Хильгетаг. Современные методы эксперимента в органической химии. М.: Хими , 1968, с. 753. :(54) СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ ПИ- РИМИдаН-2-QHOB ИЛИ ИХ СОЛЕЙ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2170734C2 (ru) * | 1995-09-06 | 2001-07-20 | Кова Ко., Лтд. | Производные пиримидина, фармацевтическая композиция и способ профилактики и лечения болезни |
Also Published As
| Publication number | Publication date |
|---|---|
| HU195195B (en) | 1988-04-28 |
| EP0123402A2 (en) | 1984-10-31 |
| US4612376A (en) | 1986-09-16 |
| ES530916A0 (es) | 1985-06-16 |
| GR81758B (OSRAM) | 1984-12-12 |
| PH22022A (en) | 1988-05-13 |
| EP0123402A3 (en) | 1985-09-18 |
| DK160492C (da) | 1991-08-26 |
| EP0123402B1 (en) | 1988-09-07 |
| CA1256107A (en) | 1989-06-20 |
| SU1436872A3 (ru) | 1988-11-07 |
| FI841128A7 (fi) | 1984-09-26 |
| NO841168L (no) | 1984-09-26 |
| DE3473875D1 (en) | 1988-10-13 |
| US4746664A (en) | 1988-05-24 |
| ES538190A0 (es) | 1985-11-01 |
| DK160492B (da) | 1991-03-18 |
| ES8505972A1 (es) | 1985-06-16 |
| KR840008333A (ko) | 1984-12-14 |
| DK166884A (da) | 1984-09-26 |
| DK166884D0 (da) | 1984-03-23 |
| FI841128A0 (fi) | 1984-03-21 |
| US4824851A (en) | 1989-04-25 |
| ES8601922A1 (es) | 1985-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1349698A3 (ru) | Способ получени производных пиримидин-2-онов или их солей | |
| SU1396963A3 (ru) | Способ получени производных дигидропиридазинона | |
| JP2003509462A (ja) | トロンボポイエチン模倣物 | |
| JPS6310154B2 (OSRAM) | ||
| RU2233278C9 (ru) | Пиримидиноновые соединения, способ их получения и фармацевтическая композиция | |
| JP2003508463A (ja) | トロンボポイエチン模倣物 | |
| CN107382966B (zh) | 一类荜茇酰胺-川芎嗪杂合物、制备方法及医药用途 | |
| CA1317597C (en) | 3,6-dihydro-1,5(2h)-pyrimidinecarboxylic acid esters | |
| JPH05331148A (ja) | カテコール誘導体、その薬学的に許容しうる塩およびエステルならびにそれらを含有する医薬組成物 | |
| JPS6363661A (ja) | ジヒドロピリジン抗アレルギ−および抗炎症剤 | |
| HU193581B (en) | Process for producing amino-pyrimidine derivatives and pharmaceutical compositions containing them | |
| US5328910A (en) | Sino-atrial node modulating pyrrolopyrimidines | |
| NZ207914A (en) | Indeno-pyridazinones and pharmaceutical compositions | |
| HUT61994A (en) | Process for producing dihydropyridine derivatives and pharmaceutical compositions with antitumoral effect comprising same | |
| JPS60214778A (ja) | Ν置換３，４−ジヒドロピリミジン誘導体ならびにその製造法および用途 | |
| US4550119A (en) | 2,4-Dihydro-5-[(substituted)phenyl]-4,4-disubstituted-3H-pyrazol-3-ones | |
| RU1779246C (ru) | Способ получени производных 1-ацил-2,3-дигидро-4 /IH/-хинолинон-4-оксима-0-сульфоновой кислоты или их солей | |
| EP0145019A2 (en) | Pyridazinone derivatives and salts thereof | |
| JPS60224692A (ja) | 新規なトリアゾロピリミジンおよびその製造法 | |
| US5215987A (en) | Substituted benzhydryl 2-hydroxypropyl piperazine derivatives | |
| US4957913A (en) | Antihypertensive polycyclic imides | |
| US4980351A (en) | 3-aminopropoxyaryl derivatives having cardiotonic and antihypertensive use and compositions thereof | |
| KR20210146296A (ko) | 티민 핵산 염기를 베이스로 하는 트리아졸로피리미딘류 및 그 제조 방법 | |
| JPS6348273A (ja) | キノロン強心剤 | |
| EA003511B1 (ru) | Производные пиперазинона и их применение |